Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 80. More products

ROSUVASTATIN CALCIUM

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C10A, C10AA) — coverage varies; not interchangeable

  • Atorvastatin (Lipitor): general benefit
  • Fluvastatin (Lescol): general benefit, Not a benefit
  • Lovastatin (Mevacor): general benefit, Not a benefit
  • Pravastatin (Pravachol): general benefit, Not a benefit
  • Simvastatin (Zocor): general benefit, Not a benefit
  • Bezafibrate (Bezalip): general benefit

9 more in the class list below

Ach-Rosuvastatin · DIN 02438917 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Rosuvastatin · DIN 02438917 Manufacturer: Accord Healthcare Inc.; listing date 2019-07-31 Health Canada: Marketed since 2019-05-23 · brand ACH-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92329 · Verify on the e-Formulary ↗ (DIN 02438917)

Source record
DIN 02438917: Ach-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id ACH Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02438917 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92329
Interchangeable products
Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended 2024-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02438917
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Rosuvastatin · DIN 02337975 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Rosuvastatin · DIN 02337975 Manufacturer: Apotex Inc.; listing date 2012-05-29 Health Canada: Marketed since 2012-04-02 · brand APO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82362 · Verify on the e-Formulary ↗ (DIN 02337975)

Source record
DIN 02337975: Apo-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02337975 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82362
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: active shortage (reported 2026-08-18, estimated to end 2026-09-18, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337975
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Rosuvastatin · DIN 02442574 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Rosuvastatin · DIN 02442574 Manufacturer: Auro Pharma Inc.; listing date 2016-04-01 Health Canada: Marketed since 2015-11-30 · brand AURO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92691 · Verify on the e-Formulary ↗ (DIN 02442574)

Source record
DIN 02442574: Auro-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id AUR Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442574 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92691
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442574
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Crestor · DIN 02265540 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Crestor (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists CRESTOR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Crestor · DIN 02265540 Manufacturer: AstraZeneca; listing date 2007-01-02 Health Canada: Marketed since 2005-03-18 · brand CRESTOR - 5MG · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Astrazeneca canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75100 · Verify on the e-Formulary ↗ (DIN 02265540)

Source record
DIN 02265540: Crestor Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id AZC Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.5177; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02265540 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75100
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02265540
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Rosuvastatin Calcium · DIN 02498332 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rosuvastatin Calcium · DIN 02498332 Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30 Health Canada: Marketed since 2025-07-15 · brand JAMP ROSUVASTATIN TABLETS · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Rosuvastatin Calcium: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98811 · Verify on the e-Formulary ↗ (DIN 02498332)

Source record
DIN 02498332: Jamp Rosuvastatin Calcium Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498332 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98811
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498332
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Rosuvastatin · DIN 02496534 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Rosuvastatin · DIN 02496534 Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29 Health Canada: Marketed since 2023-12-21 · brand M-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98639 · Verify on the e-Formulary ↗ (DIN 02496534)

Source record
DIN 02496534: M-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id MAT Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496534 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98639
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496534
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Rosuvastatin · DIN 02413051 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Rosuvastatin · DIN 02413051 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-04-01 Health Canada: Marketed since 2023-06-09 · brand MAR-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89772 · Verify on the e-Formulary ↗ (DIN 02413051)

Source record
DIN 02413051: Mar-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id MAR Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02413051 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89772
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended 2020-11-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413051
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Rosuvastatin · DIN 02397781 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Rosuvastatin · DIN 02397781 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-08-29 Health Canada: Marketed since 2026-06-15 · brand MINT-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88271 · Verify on the e-Formulary ↗ (DIN 02397781)

Source record
DIN 02397781: Mint-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id MIN Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397781 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88271
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: active shortage (reported 2025-03-18, estimated to end 2026-06-30, last updated 2026-06-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02397781
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Rosuvastatin Tablets · DIN 02536595 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Rosuvastatin Tablets · DIN 02536595 Manufacturer: Nora Pharma; listing date 2024-01-31 Health Canada: Marketed since 2023-09-14 · brand NRA-ROSUVASTATIN TABLETS · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Rosuvastatin Tablets: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102535 · Verify on the e-Formulary ↗ (DIN 02536595)

Source record
DIN 02536595: NRA-Rosuvastatin Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id NRA Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536595 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102535
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536595
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Rosuvastatin · DIN 02378523 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Rosuvastatin · DIN 02378523 Manufacturer: Pharmascience Inc.; listing date 2012-05-29 Health Canada: Marketed since 2012-03-15 · brand PMS-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86432 · Verify on the e-Formulary ↗ (DIN 02378523)

Source record
DIN 02378523: PMS-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id PMS Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02378523 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86432
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended 2018-02-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378523
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PRZ-Rosuvastatin · DIN 02505576 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PRZ-Rosuvastatin · DIN 02505576 Manufacturer: Pharmaris Canada Inc.; listing date 2022-01-31 Health Canada: Marketed since 2021-10-12 · brand PRZ-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Pharmaris canada inc · schedule Prescription
Check this DIN again · Health Canada product record

PRZ-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99494 · Verify on the e-Formulary ↗ (DIN 02505576)

Source record
DIN 02505576: PRZ-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id PRZ Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02505576 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99494
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02505576
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rosuvastatin · DIN 02405628 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Rosuvastatin · DIN 02405628 Manufacturer: Sanis Health Inc.; listing date 2016-05-31 Health Canada: Marketed since 2022-09-01 · brand ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89039 · Verify on the e-Formulary ↗ (DIN 02405628)

Source record
DIN 02405628: Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id SAI Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405628 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89039
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02405628
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rosuvastatin · DIN 02411628 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Rosuvastatin · DIN 02411628 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2024-01-12 · brand ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89622 · Verify on the e-Formulary ↗ (DIN 02411628)

Source record
DIN 02411628: Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id SIV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411628 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89622
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended 2021-06-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02411628
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Rosuvastatin · DIN 02338726 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Rosuvastatin · DIN 02338726 Manufacturer: Sandoz Canada Inc.; listing date 2012-05-29 Health Canada: Marketed since 2012-03-15 · brand SANDOZ ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82437 · Verify on the e-Formulary ↗ (DIN 02338726)

Source record
DIN 02338726: Sandoz Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id SDZ Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02338726 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82437
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended 2024-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02338726
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Rosuvastatin · DIN 02382644 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Rosuvastatin · DIN 02382644 Manufacturer: Sun Pharma; listing date 2012-05-29 Health Canada: Marketed since 2020-03-01 · brand TARO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86846 · Verify on the e-Formulary ↗ (DIN 02382644)

Source record
DIN 02382644: Taro-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id SPC Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02382644 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86846
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Teva-Rosuvastatin · DIN 02354608 · $0.1284
Shortage status: resolved shortage (ended 2024-01-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02382644
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Rosuvastatin · DIN 02354608 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Rosuvastatin · DIN 02354608 Manufacturer: Teva Canada Limited; listing date 2012-05-29 Health Canada: Marketed since 2012-03-15 · brand TEVA-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Rosuvastatin: Formulary list price $0.1284/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1284 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83977 · Verify on the e-Formulary ↗ (DIN 02354608)

Source record
DIN 02354608: Teva-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600066; group id 308; item number 0674; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1284; ministry $0.1284 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354608 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83977
Interchangeable products
Ach-Rosuvastatin · DIN 02438917 · $0.1284 Apo-Rosuvastatin · DIN 02337975 · $0.1284 Auro-Rosuvastatin · DIN 02442574 · $0.1284 Co Rosuvastatin · DIN 02339765 · $0.1284 Crestor · DIN 02265540 · $0.1284 Jamp Rosuvastatin Calcium · DIN 02498332 · $0.1284 Jamp-Rosuvastatin · DIN 02391252 · $0.1284 M-Rosuvastatin · DIN 02496534 · $0.1284 Mar-Rosuvastatin · DIN 02413051 · $0.1284 Med-Rosuvastatin · DIN 02399164 · $0.1284 Mint-Rosuvastatin · DIN 02397781 · $0.1284 NRA-Rosuvastatin · DIN 02477483 · $0.1284 NRA-Rosuvastatin Tablets · DIN 02536595 · $0.1284 PMS-Rosuvastatin · DIN 02378523 · $0.1284 PRZ-Rosuvastatin · DIN 02505576 · $0.1284 Rosuvastatin · DIN 02405628 · $0.1284 Rosuvastatin · DIN 02411628 · $0.1284 Sandoz Rosuvastatin · DIN 02338726 · $0.1284 Taro-Rosuvastatin · DIN 02382644 · $0.1284
Shortage status: resolved shortage (ended 2026-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02354608
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Rosuvastatin · DIN 02438925 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Rosuvastatin · DIN 02438925 Manufacturer: Accord Healthcare Inc.; listing date 2019-07-31 Health Canada: Marketed since 2019-05-23 · brand ACH-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Rosuvastatin: Formulary list price $0.1354/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92330 · Verify on the e-Formulary ↗ (DIN 02438925)

Source record
DIN 02438925: Ach-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id ACH Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1354; ministry $0.1354 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02438925 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92330
Interchangeable products
Apo-Rosuvastatin · DIN 02337983 · $0.1354 Auro-Rosuvastatin · DIN 02442582 · $0.1354 Co Rosuvastatin · DIN 02339773 · $0.1354 Crestor · DIN 02247162 · $0.1354 Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354 Jamp-Rosuvastatin · DIN 02391260 · $0.1354 M-Rosuvastatin · DIN 02496542 · $0.1354 Mar-Rosuvastatin · DIN 02413078 · $0.1354 Med-Rosuvastatin · DIN 02399172 · $0.1354 Mint-Rosuvastatin · DIN 02397803 · $0.1354 NRA-Rosuvastatin · DIN 02477491 · $0.1354 NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354 PMS-Rosuvastatin · DIN 02378531 · $0.1354 PRZ-Rosuvastatin · DIN 02505584 · $0.1354 Rosuvastatin · DIN 02405636 · $0.1354 Rosuvastatin · DIN 02411636 · $0.1354 Sandoz Rosuvastatin · DIN 02338734 · $0.1354 Taro-Rosuvastatin · DIN 02382652 · $0.1354 Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: resolved shortage (ended 2024-09-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02438925
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Rosuvastatin · DIN 02337983 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Rosuvastatin · DIN 02337983 Manufacturer: Apotex Inc.; listing date 2012-05-29 Health Canada: Marketed since 2012-04-02 · brand APO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Rosuvastatin: Formulary list price $0.1354/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82363 · Verify on the e-Formulary ↗ (DIN 02337983)

Source record
DIN 02337983: Apo-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1354; ministry $0.1354 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02337983 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82363
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354 Auro-Rosuvastatin · DIN 02442582 · $0.1354 Co Rosuvastatin · DIN 02339773 · $0.1354 Crestor · DIN 02247162 · $0.1354 Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354 Jamp-Rosuvastatin · DIN 02391260 · $0.1354 M-Rosuvastatin · DIN 02496542 · $0.1354 Mar-Rosuvastatin · DIN 02413078 · $0.1354 Med-Rosuvastatin · DIN 02399172 · $0.1354 Mint-Rosuvastatin · DIN 02397803 · $0.1354 NRA-Rosuvastatin · DIN 02477491 · $0.1354 NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354 PMS-Rosuvastatin · DIN 02378531 · $0.1354 PRZ-Rosuvastatin · DIN 02505584 · $0.1354 Rosuvastatin · DIN 02405636 · $0.1354 Rosuvastatin · DIN 02411636 · $0.1354 Sandoz Rosuvastatin · DIN 02338734 · $0.1354 Taro-Rosuvastatin · DIN 02382652 · $0.1354 Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: resolved shortage (ended 2025-12-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337983
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Rosuvastatin · DIN 02442582 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Rosuvastatin · DIN 02442582 Manufacturer: Auro Pharma Inc.; listing date 2016-04-01 Health Canada: Marketed since 2015-11-30 · brand AURO-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Rosuvastatin: Formulary list price $0.1354/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92692 · Verify on the e-Formulary ↗ (DIN 02442582)

Source record
DIN 02442582: Auro-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id AUR Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1354; ministry $0.1354 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442582 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92692
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354 Apo-Rosuvastatin · DIN 02337983 · $0.1354 Co Rosuvastatin · DIN 02339773 · $0.1354 Crestor · DIN 02247162 · $0.1354 Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354 Jamp-Rosuvastatin · DIN 02391260 · $0.1354 M-Rosuvastatin · DIN 02496542 · $0.1354 Mar-Rosuvastatin · DIN 02413078 · $0.1354 Med-Rosuvastatin · DIN 02399172 · $0.1354 Mint-Rosuvastatin · DIN 02397803 · $0.1354 NRA-Rosuvastatin · DIN 02477491 · $0.1354 NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354 PMS-Rosuvastatin · DIN 02378531 · $0.1354 PRZ-Rosuvastatin · DIN 02505584 · $0.1354 Rosuvastatin · DIN 02405636 · $0.1354 Rosuvastatin · DIN 02411636 · $0.1354 Sandoz Rosuvastatin · DIN 02338734 · $0.1354 Taro-Rosuvastatin · DIN 02382652 · $0.1354 Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: resolved shortage (ended 2021-06-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442582
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Crestor · DIN 02247162 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Crestor (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists CRESTOR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Crestor · DIN 02247162 Manufacturer: AstraZeneca; listing date 2003-09-04 Health Canada: Marketed since 2003-02-19 · brand CRESTOR - 10MG · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Astrazeneca canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71404 · Verify on the e-Formulary ↗ (DIN 02247162)

Source record
DIN 02247162: Crestor Raw flags: chronicUseMed=Y, sec3=Y Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id AZC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6117; ministry $0.1354 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247162 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71404
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354 Apo-Rosuvastatin · DIN 02337983 · $0.1354 Auro-Rosuvastatin · DIN 02442582 · $0.1354 Co Rosuvastatin · DIN 02339773 · $0.1354 Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354 Jamp-Rosuvastatin · DIN 02391260 · $0.1354 M-Rosuvastatin · DIN 02496542 · $0.1354 Mar-Rosuvastatin · DIN 02413078 · $0.1354 Med-Rosuvastatin · DIN 02399172 · $0.1354 Mint-Rosuvastatin · DIN 02397803 · $0.1354 NRA-Rosuvastatin · DIN 02477491 · $0.1354 NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354 PMS-Rosuvastatin · DIN 02378531 · $0.1354 PRZ-Rosuvastatin · DIN 02505584 · $0.1354 Rosuvastatin · DIN 02405636 · $0.1354 Rosuvastatin · DIN 02411636 · $0.1354 Sandoz Rosuvastatin · DIN 02338734 · $0.1354 Taro-Rosuvastatin · DIN 02382652 · $0.1354 Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247162
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Rosuvastatin Calcium · DIN 02498340 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Rosuvastatin Calcium · DIN 02498340 Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30 Health Canada: Marketed since 2025-07-16 · brand JAMP ROSUVASTATIN TABLETS · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Rosuvastatin Calcium: Formulary list price $0.1354/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98812 · Verify on the e-Formulary ↗ (DIN 02498340)

Source record
DIN 02498340: Jamp Rosuvastatin Calcium Raw flags: chronicUseMed=Y, sec3=Y Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1354; ministry $0.1354 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498340 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98812
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354 Apo-Rosuvastatin · DIN 02337983 · $0.1354 Auro-Rosuvastatin · DIN 02442582 · $0.1354 Co Rosuvastatin · DIN 02339773 · $0.1354 Crestor · DIN 02247162 · $0.1354 Jamp-Rosuvastatin · DIN 02391260 · $0.1354 M-Rosuvastatin · DIN 02496542 · $0.1354 Mar-Rosuvastatin · DIN 02413078 · $0.1354 Med-Rosuvastatin · DIN 02399172 · $0.1354 Mint-Rosuvastatin · DIN 02397803 · $0.1354 NRA-Rosuvastatin · DIN 02477491 · $0.1354 NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354 PMS-Rosuvastatin · DIN 02378531 · $0.1354 PRZ-Rosuvastatin · DIN 02505584 · $0.1354 Rosuvastatin · DIN 02405636 · $0.1354 Rosuvastatin · DIN 02411636 · $0.1354 Sandoz Rosuvastatin · DIN 02338734 · $0.1354 Taro-Rosuvastatin · DIN 02382652 · $0.1354 Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498340
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Rosuvastatin · DIN 02496542 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Rosuvastatin · DIN 02496542 Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29 Health Canada: Marketed since 2024-02-28 · brand M-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Rosuvastatin: Formulary list price $0.1354/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98640 · Verify on the e-Formulary ↗ (DIN 02496542)

Source record
DIN 02496542: M-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id MAT Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1354; ministry $0.1354 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496542 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98640
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354 Apo-Rosuvastatin · DIN 02337983 · $0.1354 Auro-Rosuvastatin · DIN 02442582 · $0.1354 Co Rosuvastatin · DIN 02339773 · $0.1354 Crestor · DIN 02247162 · $0.1354 Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354 Jamp-Rosuvastatin · DIN 02391260 · $0.1354 Mar-Rosuvastatin · DIN 02413078 · $0.1354 Med-Rosuvastatin · DIN 02399172 · $0.1354 Mint-Rosuvastatin · DIN 02397803 · $0.1354 NRA-Rosuvastatin · DIN 02477491 · $0.1354 NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354 PMS-Rosuvastatin · DIN 02378531 · $0.1354 PRZ-Rosuvastatin · DIN 02505584 · $0.1354 Rosuvastatin · DIN 02405636 · $0.1354 Rosuvastatin · DIN 02411636 · $0.1354 Sandoz Rosuvastatin · DIN 02338734 · $0.1354 Taro-Rosuvastatin · DIN 02382652 · $0.1354 Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496542
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Rosuvastatin · DIN 02413078 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Rosuvastatin · DIN 02413078 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-04-01 Health Canada: Marketed since 2023-06-09 · brand MAR-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Rosuvastatin: Formulary list price $0.1354/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89773 · Verify on the e-Formulary ↗ (DIN 02413078)

Source record
DIN 02413078: Mar-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id MAR Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1354; ministry $0.1354 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02413078 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89773
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354 Apo-Rosuvastatin · DIN 02337983 · $0.1354 Auro-Rosuvastatin · DIN 02442582 · $0.1354 Co Rosuvastatin · DIN 02339773 · $0.1354 Crestor · DIN 02247162 · $0.1354 Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354 Jamp-Rosuvastatin · DIN 02391260 · $0.1354 M-Rosuvastatin · DIN 02496542 · $0.1354 Med-Rosuvastatin · DIN 02399172 · $0.1354 Mint-Rosuvastatin · DIN 02397803 · $0.1354 NRA-Rosuvastatin · DIN 02477491 · $0.1354 NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354 PMS-Rosuvastatin · DIN 02378531 · $0.1354 PRZ-Rosuvastatin · DIN 02505584 · $0.1354 Rosuvastatin · DIN 02405636 · $0.1354 Rosuvastatin · DIN 02411636 · $0.1354 Sandoz Rosuvastatin · DIN 02338734 · $0.1354 Taro-Rosuvastatin · DIN 02382652 · $0.1354 Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: active shortage (reported 2017-04-01, last updated 2018-12-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413078
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Rosuvastatin · DIN 02397803 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Rosuvastatin · DIN 02397803 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-08-29 Health Canada: Marketed since 2026-06-16 · brand MINT-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Rosuvastatin: Formulary list price $0.1354/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1354 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88272 · Verify on the e-Formulary ↗ (DIN 02397803)

Source record
DIN 02397803: Mint-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600044; group id 308; item number 0675; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1354; ministry $0.1354 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397803 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88272
Interchangeable products
Ach-Rosuvastatin · DIN 02438925 · $0.1354 Apo-Rosuvastatin · DIN 02337983 · $0.1354 Auro-Rosuvastatin · DIN 02442582 · $0.1354 Co Rosuvastatin · DIN 02339773 · $0.1354 Crestor · DIN 02247162 · $0.1354 Jamp Rosuvastatin Calcium · DIN 02498340 · $0.1354 Jamp-Rosuvastatin · DIN 02391260 · $0.1354 M-Rosuvastatin · DIN 02496542 · $0.1354 Mar-Rosuvastatin · DIN 02413078 · $0.1354 Med-Rosuvastatin · DIN 02399172 · $0.1354 NRA-Rosuvastatin · DIN 02477491 · $0.1354 NRA-Rosuvastatin Tablets · DIN 02536609 · $0.1354 PMS-Rosuvastatin · DIN 02378531 · $0.1354 PRZ-Rosuvastatin · DIN 02505584 · $0.1354 Rosuvastatin · DIN 02405636 · $0.1354 Rosuvastatin · DIN 02411636 · $0.1354 Sandoz Rosuvastatin · DIN 02338734 · $0.1354 Taro-Rosuvastatin · DIN 02382652 · $0.1354 Teva-Rosuvastatin · DIN 02354616 · $0.1354
Shortage status: active shortage (reported 2025-03-18, estimated to end 2026-06-30, last updated 2026-06-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02397803
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

EVOLOCUMAB

· 1 products · Limited Use, codes 527, 737 · strengths: 140mg/mL · Inj Sol-Pref Syr Autoinj Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications CRESTOR (rosuvastatin calcium tablets) is indicated in adults as an adjunct to diet, at least equivalent to the Adult Treatment Panel III (ATP III TLC diet), for the reduction of elevated total cholesterol (Total-C), LDL-C, ApoB, the Total-C/HDL-C ratio and triglycerides (TG) and for increasing HDL-C; in hyperlipidemic and dyslipidemic conditions, when response to diet and exercise alone has been inadequate including: • Primary hypercholesterolemia (Type IIa including heterozygous familial hypercholesterolemia and severe non-familial hypercholesterolemia) • Combined (mixed) dyslipidemia (Type IIb) • Homozygous familial hypercholesterolemia where CRESTOR is used either alone or as an adjunct to diet and other lipid lowering treatments such as apheresis. In adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease (see 14 Clinical Trials), CRESTOR is indicated to: • Reduce the risk of nonfatal myocardial infarction • Reduce the risk of nonfatal stroke • Reduce the risk of coronary artery revascularization 1.1. Pediatrics Pediatrics (10 to <18 yea… https://pdf.hres.ca/dpd_pm/00085771.PDF PM date: 2026-08-12 Source product: CRESTOR - 10MG; DIN 02247162; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Rosuvastatin · DIN 02337975 Shortage status: active shortage (reported 2026-08-18, estimated to end 2026-09-18, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337975

Check this DIN again

Mint-Rosuvastatin · DIN 02397781 Shortage status: active shortage (reported 2025-03-18, estimated to end 2026-06-30, last updated 2026-06-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02397781

Check this DIN again

Mar-Rosuvastatin · DIN 02413078 Shortage status: active shortage (reported 2017-04-01, last updated 2018-12-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413078

Check this DIN again

Mint-Rosuvastatin · DIN 02397803 Shortage status: active shortage (reported 2025-03-18, estimated to end 2026-06-30, last updated 2026-06-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02397803

Check this DIN again